Antipsychotic drugs are central to the treatment of schizophrenia and other psychotic
disorders but are ineffective for some patients and associated with side-effects and …

A recent increase in the literature regarding the evidence base for clozapine has made it
increasingly difficult for clinicians to judge “best evidence” for clozapine use. As such, we …

Background Impairment in a wide range of cognitive abilities has been consistently reported
in individuals with schizophrenia. Both neurocognitive and social cognitive deficits are …

Despite effective pharmacological treatments for psychotic symptoms (eg, hallucinations,
delusions), functional outcomes for people with psychotic disorders are often disappointing …

Cognitive deficits are a core aspect of psychotic disorders; however, it is not clear to which
extent different pharmacological treatments could distinctly impact these outcomes. Hence …

Cognitive impairment is a core feature of schizophrenia (SZ) and bipolar disorder (BD). A
neurocognitive profile characterized by widespread cognitive deficits across multiple …

Since the introduction of chlorpromazine and throughout the development of the new-
generation antipsychotic drugs (APDs) beginning with clozapine, the D 2 receptor has been …

Cognitive impairment is a core symptom domain of schizophrenia. The effect of
antipsychotics, the cornerstone of treatment in schizophrenia, on this domain is not fully …

Background Because of the debate about whether second-generation antipsychotic drugs
are better than first-generation antipsychotic drugs, we did a meta-analysis of randomised …

Antipsychotic drugs (APDs) are best classified as typical or atypical. The distinction is based
solely on their ability to cause extrapyramidal side effects (EPS), including tardive dyskinesia …